Provectus Pharmaceuticals, Inc. Added to Cancer Immunotherapy Index by Mentor Capital, Inc. Experiences 23% One-Week Gain

(For Immediate Release, March 1, 2010)

SAN DIEGO, Mentor Capital, Inc. (PINK SHEETS:MNTR) announced today that it has added Provectus Pharmaceuticals, Inc. (PVCT:OB) to Mentor Capital's proprietary Cancer Immunotherapy Index effective as of February 22, 2010. To add Provectus to the CI Index, Mentor Capital has recently taken a significant initial position in Provectus through Mentor Capital's managed fund. Mentor notes that Provectus has advanced 23% during this first trading week on the Index and those results are reported on the current CI Index update.

Mentor Capital CEO, Chet Billingsley, highlights, "Provectus has the strong balance sheet, executive and science teams, and especially the breakthrough medical technology that warrants long-term inclusion on the Cancer Immunotherapy Index that we look for and that merits substantial institutional interest."

Provectus targets Melanoma, which is a particularly deadly form of cancer affecting 62,000 and killing 8,000 patients in the USA each year. Cancerous Melanocytes are especially lethal because in their natural form they move ameba-like to lay out protecting melanin rather than staying bound in the static formations of their skin cell brethren. The lesions are inherently metastatic.

In the Provectus treatment regime, these lesions are injected with PV-10, a very specialized version of the red dye, Rose Bengal, that ophthalmologists use to test for corneal scratches because it is preferentially absorbed by damaged cells. The smooth lipid layer of healthy cell membranes excludes the Rose Bengal product like wax paper sheds water. Cancerous cells are often physically or chemically irregular and the PV-10 penetrates into the cell as water would find its way through the thinner creases in wax paper that has been tightly crumpled. Because of PH differences, the cancerous cells continue to uptake more and more PV-10, which is further pulled into lysosomes (cell stomachs) until these rupture, leading to a complete rupture of the cancer cell.

The cold cell rupture casts whole cancer protein fragments adrift that have not been chemically modified by heat, chemicals or radiation. These unaltered cancer fragments in the otherwise healthy tissue excite an immune response to those cancer proteins in the lesion location. When a piece of cancer protein is passed to a killer T-Cell, that T-Cell will spend the rest of its days bouncing through the blood stream looking to match up that protein once more and attack.

If the T-Cell does find another matching cancer protein on the surface of a Melanoma cell that has slipped away, it latches on. Then the T-Cell secretes perforin which punches holes in the cell membrane allowing the cytoplasm to ooze out. Enzymes are injected that dissolve the mitochondria that power cell functions, and finally, granzymes are injected that chop up the DNA in the nucleus like a molecular Pac-Man.

Because the Provectus PV-10 treatment gives rise to this robust immunotherapy response PV-10 is a natural candidate to be the first choice standard treatment for all Melanoma cases with a 69% objective response being reported. If needed, follow-on cancer treatments of other sorts can be applied. They will be buttressed by the PV-10 immunotherapy effect that has recorded an objective response of 27% to 44% in even untreated or bystander lesions. In addition to Melanoma treatments, PV-10 may also be applicable to breast, liver or perhaps any other well defined solid tumor that can be targeted for treatment injections.

The conclusions and discussions herein, while derived from published materials, are Mentor Capital's independent analysis of the underlying medical science. News updates and the weekly public market progress for Provectus and that of the ten other companies in the Cancer Immunotherapy Index can be followed in detailed updates presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

For further information contact:

Chet Billingsley, CEO
Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065 (760) 788 - 4700